Galusic D, Lucijanic M, Livun A, et al. - In unfractionated bone-marrow aspirates of 43 individuals with myelofibrosis (28 primary-/PMF, 15 secondary-myelofibrosis/SMF) and 12 controls, researchers examined aurora-kinase-A (AURKA), BORA and Polo-like-kinase-1 (PLK1) mRNA expression and evaluated their clinical relationships. Findings revealed that there was no significant difference in AURKA expression between myelofibrosis and controls. Higher AURKA expression was significantly linked to higher absolute monocyte-count and shorter overall survival. Higher BORA expression was significantly linked to the absence of constitutional symptoms, absence of circulatory blasts, higher monocyte- and higher eosinophil-counts and had neutral impact on survival. In the pathogenesis of myelofibrosis, AURKA, BORA and PLK1 were involved and can affect survival. Future studies are warranted to investigate these interesting associations.